ROIV

NASDAQ 已收盘

Roivant Sciences

38.96 USD
▲+0.23+0.59%
盘后 39.22 +0.67%
2026-11-19
市值
$28.21B
市盈率
—
EPS
-0.59
股息率
—
52 周区间
19.96 – 42.50
成交量
4.93M
Beta
1.20
目标价
50.82
52W 低 19.9652W 高 42.50
价格走势

公司简介

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh...

关联新闻